Navigation Links
Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Article Published in Recent Issue of Journal Blood

NEW YORK, April 11, 2007 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the publication of a research article on Atiprimod, Callisto's drug currently in clinical trials in carcinoid cancer and multiple myeloma patients, in the February 2007 issue of Blood, a peer-reviewed scientific journal that publishes original research articles related to hematological malignancies.

The article authored by Dr. Michael Wang and Dr. Qing Yi, from the University of Texas M.D. Anderson Cancer Center, focuses on Atiprimod's ability to inhibit proliferation of mantle cell lymphoma (MCL) cells in vitro and to inhibit growth of MCL tumors in tumor-bearing mice. The animal data demonstrated that Atiprimod significantly inhibited tumor growth in vivo and prolonged survival of tumor-bearing mice. Atiprimod was shown to enhance release of apoptosis-inducing factor (AIF) from cellular mitochondria, and the authors suggest that this is the mechanism of Atiprimod's apoptotic (programmed cellular death) activity.

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

The publication appeared in Blood First Edition Paper, prepublished online February 22, 2007 DOI 10.1182/Blood-2006-12-063958 and is titled: "Atiprimod inhibits the growth of mantle cell lymph
'"/>




Page: 1 2 3

Related medicine technology :

1. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
(Date:8/21/2014)... Aspen Advisors, a U.S.-based healthcare consulting firm, announced today that ... Best Places to Work in Healthcare for 2014. ... creating workplaces that enable employees to perform at their optimum ... an employee engagement and satisfaction survey. This is the ... a “Best Places to Work in Healthcare”. , "We are ...
(Date:8/21/2014)... Absence seizures are believed to be elicited by ... of the brain that regulate influxes of calcium. ... generate burst firing, leading the neurons to enter ... the relationship between burst firing and absence seizures, ... seizures in mice using gene targeting techniques to ...
(Date:8/21/2014)... According to researchers at the University of Montreal, the ... important role as we train our bodies, movements and, ... sleep. While researchers knew that sleep helped us the ... known why. "The subcortical regions are important in information ... When consolidation level is measured after a period of ...
(Date:8/21/2014)... August 21, 2014 Bedros Keuilian’s Annual Fitness ... the industry, attended by many people already earning seven-figure incomes. ... is usually only open to the owners of Keuilian’s ... , This year’s Fit Body Boot Camp World Conference will ... a fitness boot camp or are struggling with ...
(Date:8/21/2014)... Minn. (PRWEB) August 21, 2014 ... social wellness solutions, announced today that it has entered ... medical best practices, mobile technology and predictive analytics for ... communities. , According to Michael Emerson , ... applied for two patents on the technology used in ...
Breaking Medicine News(10 mins):Health News:Modern Healthcare Names Aspen Advisors Among the Top 100 Employers in the Healthcare Industry for a Fourth Consecutive Year 2Health News:Learning to play the piano? Sleep on it! 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2
... Cancers and Colorectal Screening Among Key ProvisionsBETHESDA, Md., ... and its more than 10,000 physician members congratulate ... today for the introduction of "21st Century Cancer ... Treatment) Act" and their vow to renew the ...
... The ,Help is Here Express, bus tour will be ... 3 at various cities throughout the state in order ... programs that provide prescription medicines for free or nearly ... exceeding that of the nation (8.1 percent), the Partnership ...
... 26 BioMosaics Inc., a cancer biomarker ... antibody product (clone 1G12) for detection of ... as an immunohistochemical test for diagnosis of ... Laboratories is a state-of-the-art reference pathology laboratory ...
... average sodium intake far exceeds recommendations, raising health risks, ... American consumes far more salt each day than is ... from the U.S. Centers for Disease Control and Prevention ... high blood pressure, blacks, and middle-age and older adults ...
... new study by researchers at the University of British Columbia ... The study, published in the Journal of Public Health ... three times more likely than those who don,t to meet ... of physical activity. , Doctoral student Ugo Lachapelle and Assoc. ...
... Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: ... completed its acquisition of Genentech pursuant to a short-form ... the Roche Group. Roche had announced earlier in the ... expired on Wednesday, March 25. In connection with the ...
Cached Medicine News:Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:Using Too Much Salt Is Common in U.S., CDC Says 2Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:Roche Completes Acquisition of Genentech 2
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: